Geoffrey B. Thompson

Geoffrey B. Thompson

Auto-generated profile, based on publicly available information

Geoffrey B. Thompson

Department of Surgery, Mayo Clinic, Rochester, MN, USA

Research Focus & Metrics

Academic Career Length

32Years (1995-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 April 2006 in British Journal of Surgery
Verified
Journal Article
Closed access
PDF file
STS. G. Tipton
S. G. Tipton
TST. C. Smyrk
T. C. Smyrk
MSM. G. Sarr
M. G. Sarr
GTG. B. Thompson
G. B. Thompson

1 January 2003 in Current Opinion in Oncology
Verified
Journal Article
Closed access
GTGeoffrey B. Thompson
Geoffrey B. Thompson
WYWilliam F. Young
William F. Young
Adrenal incidentalomas are incidentally discovered adrenal masses greater than 1 cm in diameter that appear to be clinically nonfunctioning. They are detected during imaging procedures of the abdomen and chest (CT, MRI, and ultrasonography) for an unrelated condition or symptom complex. With the widespread escalation in the use of these imaging modalities and marked improvements in image resolution, the probability of finding an incidentaloma on cross-section imaging is rapidly approaching the 6% prevalence of previously reported autopsy studies. All incidentalomas greater than 1 cm should be evaluated for hormonal activity, including a 1-mg overnight dexamethasone suppression test, total 24-hour urinary metanephrines and fractionated catecholamines, and, in the hypertensive patient, a serum potassium level and plasma aldosterone concentration to plasma renin activity ratio. All hormonally active tumors should be removed. Hormonally inactive tumors are resected based on size, imaging phenotype, and interval growth. Percutaneous biopsies are generally unwarranted and are potentially dangerous. Laparoscopic adrenalectomy has become the surgical procedure of choice for most benign functioning and nonfunctioning tumors of the adrenal gland. Subclinical metabolic abnormalities associated with adrenal incidentalomas remain an area of intense clinical research.

1 June 2002 in Archives of Surgery
Verified
Journal Article
Open access
PDF file
MBMercedeh Baghai
Mercedeh Baghai
GTGeoffrey B. Thompson
Geoffrey B. Thompson
WYWilliam F. Young
William F. Young
CGClive S. Grant
Clive S. Grant
VMVirginia V. Michels
Virginia V. Michels
JHJon A. van Heerden
Jon A. van Heerden
VON HIPPEL–LINDAU disease (VHL) is an autosomal dominant tumor predisposition syndrome, characterized by multiple benign and malignant tumors of the central nervous system, kidneys, pancreas, adrenal glands, and paraganglia. Retinal angiomas and central nervous system (CNS) hemangioblastomas are the hallmarks of this disease. Renal cell carcinomas are the most malignant and lethal tumor, seen in more than 50% of patients.1-3 Benign cystic lesions of the kidneys, pancreas, epididymis, ovaries, and endolymphatic sac also have been described. Pancreatic (nonfunctioning) neuroendocrine tumors are seen much less frequently. Pheochromocytomas and paragangliomas, although rare, pose a significant threat because of the sudden and unsuspected release of catecholamines. Sudden death is a major concern, particularly in the perioperative and peripartum periods. In large series, the frequency of pheochromocytomas and paragangliomas in patients with VHL varies between 7% and 20%.1,4

1 May 2002 in Archives of Surgery
Verified
Journal Article
Open access
PDF file
JSJuan M. Sarmiento
Juan M. Sarmiento
GTGeoffrey B. Thompson
Geoffrey B. Thompson
DNDavid M. Nagorney
David M. Nagorney
JDJohn H. Donohue
John H. Donohue
MFMichael B. Farnell
Michael B. Farnell
DUODENAL POLYPOSIS is an uncommon diagnosis. It occurs in 2 different settings—in patients with familial adenomatous polyposis (FAP) in whom the polyps are often multiple and numerous and in patients with isolated villous tumors in whom the polyps are usually single and large, often centered around the papilla of Vater. In patients with FAP, the incidence of duodenal adenocarcinoma has been calculated to be 200 to 300 times greater than that of the general population.1 Accepting the adenoma-carcinoma sequence, and according to our experience with isolated villous tumors of the duodenum,2 it is clear that these growths have increased malignant potential. For many years, surgical judgment has dictated the need for control of these lesions as a prophylactic measure for duodenal-ampullary carcinoma. Following proctocolectomy for polyposis, duodenal adenocarcinoma is the most common cause of malignancy-associated death in patients with FAP. Specifically, in this latter group of patients, transduodenal excision has been considered good treatment provided that the polyp does not harbor invasive cancer.2,3 Recurrences are more difficult to treat, however, and surgical scarring often precludes a proper anatomical dissection in and around the ampulla of Vater.

15 January 2008 in World Journal of Surgery
Verified
Journal Article
Closed access
PDF file
JPJohn R. Porterfield
John R. Porterfield
GTGeoffrey B. Thompson
Geoffrey B. Thompson
WYWilliam F. Young
William F. Young
JCJohn T. Chow
John T. Chow
RFRaymond S. Fryrear
Raymond S. Fryrear
CGClive S. Grant
Clive S. Grant

1 December 1998 in Surgery
Verified
Journal Article
Closed access
PDF file
IHIan Hay
Ian Hay
CGClive S. Grant
Clive S. Grant
EBErik J. Bergstralh
Erik J. Bergstralh
GTGeoffrey B. Thompson
Geoffrey B. Thompson
JHJon A. van Heerden
Jon A. van Heerden
JGJohn R. Goellner
John R. Goellner